Financial Performance - Sisram Medical's revenue decreased by 1.9% year-over-year to $165.5 million in H1 2025 [9, 71], but excluding North America, revenue grew 7.1% YoY [71] - Gross profit margin decreased by 2.4 percentage points to 60.0% [9, 71], due to product mix and decreased North America revenue [71] - Injectables revenue increased significantly by 218.1% year-over-year [9, 79], driven by geographical expansion and commercialization efforts [80] - Net profit decreased by 31.9% [70] Regional Performance - North America revenue decreased by 15.6% [10, 75] due to market headwinds [75] - APAC revenue increased by 17.6% [10, 75] due to the "Go-Direct" strategy [75] - Europe revenue declined slightly by 0.8% [75], but new EBD platforms saw notable growth [75] - Middle East and Africa revenue decreased by 9.7% [76] due to geopolitical tensions [76] Strategic Initiatives - The company is preparing for the launch of DAXXIFY in mainland China in H2 2025 [13, 45, 86] - The company is expanding global penetration of Alma Harmony, Alma IQ, and Universkin by Alma [86] - The company is driving injectables portfolio Revanesse and Profhilo growth in key markets [86] - The company is developing direct-sales offices in strategic regions [86]

Stock Code: 2018.HK 2025 Interim Results P&L Summary | | 1H 2025 | 1H 2024 | YoY | | --- | --- | --- | --- | | （RMB mn） | | | | | Revenue | 13,318 | 11,247 | +18.4% | | Gross Profit | 2,754 | 2,418 | +13.9% | | Research and Development Costs | 998 | 949 | +5.1% | | Distribution and Selling Expenses | 343 | 297 | +15.4% | | Administrative Expenses | 637 | 566 | +12.6% | | Net Profit* | 876 | 537 | +63.1% | | Basic EPS (RMB） | 0.76 | 0.46 | +65.2% | *Net profit represents profit attributable to owners of the ...

INTERIM RESULTS 2025 Corporate Presentation August 2025 Financial Highlights Business Review Outlook Near Term AGENDA Open Forum Financial Highlights Priorities and Opportunities ◼ Hygiene Products Further consolidate leading position by expanding market share of upgrade and premium products ◼ Tissue Paper Revenue growth and market share expansion driven by product upgrade and premiumisation, and stable pricing strategy, outperform the sales performance of the market Mid Term ◼ Implementation of Core Strate ...

東方海外（國際）有限公司 2025 Interim Results | 2025 年中期業績 2 (1) The information/contents herein includes both data provided from Orient Overseas (International) Limited ("OOIL") and its affiliates and data obtained from relevant third-party information provider(s). Such information/contents is purely intended for your reference only and is subject to changes/updates at any time without further notice. (2) The information/contents herein is not a recommendation, an offer to buy, sell or trade in nor solicitation of an ...

Financial Performance - The company's revenue increased by 3.4% from RMB 74,412 million in 1H2024 to RMB 76,939 million in 1H2025 [8] - Net profit saw a slight increase of 0.2%, rising from RMB 2,125 million in 1H2024 to RMB 2,129 million in 1H2025 [8] - Gross profit decreased by 2.8% from RMB 8,116 million to RMB 7,888 million [8] - Operating profit increased by 6.3% from RMB 1,481 million in 1H2023 to RMB 1,706 million in 1H2025 [12] - SG&A expenses decreased by 5.5% from RMB 6,542 million to RMB 6,182 million [86] Business Segments - Telecommunications Infrastructure Services (TIS) revenue increased by 1.6%, from RMB 37,666 million in 1H2024 to RMB 38,272 million in 1H2025 [15] - Business Process Outsourcing (BPO) services revenue increased by 1.0%, from RMB 22,163 million in 1H2024 to RMB 22,383 million in 1H2025 [15] - Applications, Content and Other Services (ACO) revenue increased significantly by 11.7%, from RMB 14,583 million in 1H2024 to RMB 16,284 million in 1H2025 [15] Market Performance - Domestic Non-operator market revenue increased by 12.9% [15] - Overseas market revenue increased by 8.7% [15] - Domestic Operator market revenue decreased by 4.6% [15] Strategic Initiatives - New contracts of strategic emerging businesses in 1H2025 exceeded RMB 42 billion, representing an increase of over 10% year-on-year [26] - Digital infrastructure new contracts increased by over 20% [30] - Smart city new contracts increased by over 15% [34]

Financial Performance - Total revenues and other income increased by 6% to US$1242 million in 1H 2025 [12] - Core lease rental contribution increased by 24% to US$342 million in 1H 2025 [12] - Core net profit after tax increased by 20% to US$342 million in 1H 2025 [12] - Operating cash flow net of interest reached US$1 billion in 1H 2025 [67] Balance Sheet and Portfolio - Total assets increased by 2% to US$256 billion as of June 30, 2025 [13] - Total equity increased by 2% to US$65 billion as of June 30, 2025 [13] - Total liquidity was US$61 billion as of June 30, 2025 [13] - The company's portfolio exceeded 830 aircraft and engines [31] Dividends and Lease Terms - The 2025 interim dividend per share is US$01476, the second highest on record [16] - The average remaining lease term is 79 years [47] Future Growth - The company has a record total future committed capex of US$20 billion [82]

Financial Performance - Revenue decreased by 9.87% from RMB 26,471.527 million in 1H2024 to RMB 23,857.644 million in 1H2025[12] - Fuel costs decreased by 26.16% from RMB -7,922.234 million in 1H2024 to RMB -5,849.834 million in 1H2025[12] - Depreciation increased by 11.29% from RMB -6,070.658 million in 1H2024 to RMB -6,755.962 million in 1H2025[12] - Operating profit increased by 1.94% from RMB 7,466.308 million in 1H2024 to RMB 7,611.019 million in 1H2025[12] - Profit attributable to equity holders of the company increased by 1.16% from RMB 2,802.197 million in 1H2024 to RMB 2,834.655 million in 1H2025[12] - Total assets increased by 3.60% from RMB 340,455.547 million on 2024.12.31 to RMB 352,714.191 million on 2025.06.30[13] - Total liabilities increased by 2.96% from RMB 232,923.154 million on 2024.12.31 to RMB 239,821.682 million on 2025.06.30[13] Operational Data - The ratio of clean energy revenue increased from 60.29% in 1H2024 to 64.20% in 1H2025[23] - Consolidated capacity increased by 6.99% from 39,869.7 MW on 2024.6.30 to 42,658.8 MW on 2025.6.30[25] - Net power generation decreased by 2.8% from 64,344 GWh in 1H2024 to 62,537 GWh in 1H2025[31]

ck Code : 1093) 2025 Interim Results Presentation Aug. 2025 ININI China's Leading Innovative Pharmaceutical Enterprise R&D Capabilities 00 5 capacity of 250,000L R&D centers located in R&D platforms China & the U.S. 201010 + - 2401 Innovative drugs and R&D professionals new formulations Manufacturing Capabilities Commercialization Capabilities 2 10+ Production bases for pharmaceutical products Nano formulation production capacity of 20M doses/year; Biologics fermentation Chemical drugs production capacity o ...

2025 First Half Investor Presentation A u g 2 0 2 5 Legal Disclaimer 2 • This document has been prepared by YEAHKA LIMITED (the "Company" or "us") for a limited number of recipients and for information purposes only and not for public dissemination. You and your directors, officers, employees, agents and affiliates must hold this document and any oral information provided in connection with this document in strict confidence and may not communicate, reproduce, distribute or disclose it to any other person, ...

2025 INTERIM RESULTS PRESENTATION 21 August 2025 DISCLAIMER This document ("document") has been prepared by AIA Group Limited (the "Company", and together with its subsidiaries, "AIA", the "Group" or "AIA Group") solely for use at the presentation held in connection with the announcement of the Company's financial results (the "Presentation"). References to "document" in this disclaimer shall be construed to include any oral commentary, statements, questions, answers and responses at the Presentation. No re ...